Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUPAT-09: nal-IRI + 5-FU/levofolinate vs FOLFIRINOX as second-line therapy for pancreatic cancer
jRCT1041200082Phase 2Recruiting
- Start
- Dec 2020
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan liposome in pancreatic cancer (PC) (2 arms). Primary endpoint: Overall survival. Started Dec 2020; status: recruiting.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT1041200082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041200082.